Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects – A double blind, randomized, placebo-controlled, cross-over clinical trial

Kirsten, Anne; Watz, Henrik; Kretschmar, Gunther; Pedersen, Frauke; Bock, Daniel; Meyer‐Sabellek, W.; Magnussen, H

doi:10.1016/j.pupt.2011.04.029

Cited by 26 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized, double-blind, placebocontrolled clinical trial, inhaled bimosiamose reduced allergen-induced late allergy response in mild asthmatic patients [129]. Bimosiamose also effectively attenuated ozone-induced airway inflammation in healthy patients, inhibiting neutrophil infiltration in the lung and reducing the accumulation of IL-8 and MMP-9 in sputum of treated patients [130]. Notably, inhaled bimosiamose attenuated airway inflammation in patients with chronic obstructive pulmonary disease, reducing the number of macrophages and lowering the concentration of IL-8 and MMP-9 in sputum [131].…”

Section: Antiselectin Therapeutic Aproachesmentioning

confidence: 99%

“…Overall, these data suggest that drugs able to interfere with selectin-mediated adhesive interactions represent promising therapeutic approaches in inflammatory diseases. Of note, available clinical data suggest that anti selectin drug delivery directly to the target organ (e.g., cylexin in the cardiopulmonary bypass circuit [128] or inhaled/ subcutaneous bimosiamose [129][130][131][132]) is more effective than the systemic treatment [123][124][125][126]. However, these results may be ascribed to the fact that, apart from GMI-1070, pan-selectin therapies were never tested systemically, like antiselectin antibodies or PSGL-1-Ig fusion protein [123][124][125][126].…”

Section: Antiselectin Therapeutic Aproachesmentioning

confidence: 99%

See 1 more Smart Citation

Selectins and Their Ligands as Potential Immunotherapeutic Targets in Neurological Diseases

Angiari

Constantin

2013

Immunotherapy

View full text Add to dashboard Cite

Selectins are a family of adhesion receptors that bind to highly glycosylated molecules expressed on the surface of leukocytes and endothelial cells. The interactions between selectins and their ligands control tethering and rolling of leukocytes on the vascular wall during the process of leukocyte migration into the tissues under physiological and pathological conditions. In recent years, it has been shown that leukocyte recruitment in the CNS plays a pivotal role in diseases such as multiple sclerosis, ischemic stroke, epilepsy and traumatic brain injury. In this review, we discuss the role of selectins in leukocyte-endothelial interactions in the pathogenesis of neurological diseases, highlighting new findings suggesting that selectins and their ligands may represent novel potential therapeutic targets for the treatment of CNS diseases.

show abstract

Section: Antiselectin Therapeutic Aproachesmentioning

confidence: 99%

Section: Antiselectin Therapeutic Aproachesmentioning

confidence: 99%

Selectins and Their Ligands as Potential Immunotherapeutic Targets in Neurological Diseases

Angiari

Constantin

2013

Immunotherapy

View full text Add to dashboard Cite

show abstract

“…78 patients with respiratory disease were recruited from respiratory clinics. The diagnostic criteria for the conditions have been described previously [5]. Six current smokers and four males taking angiotensin converting enzyme inhibitors (ACEi) were also recruited.…”

Section: To the Editormentioning

confidence: 99%

“…The patients with respiratory disease had the following diagnoses: unexplained chronic cough (n56), asthma (n53), eosinophilic bronchitis (n52) and chronic obstructive pulmonary disease (n51). A capsaicin cough challenge was performed after removal of the cough monitor [5]. Sputum was induced and processed as described previously [7].…”

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers

et al. 2012

View full text Add to dashboard Cite

Evaluation of New Drugs for Asthma and COPD: Endpoints, Biomarkers and Clinical Trial Design

Singh

2016

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

There remains a considerable need to develop novel therapies for patients with asthma and chronic obstructive pulmonary disease (COPD). The greatest challenge at the moment is measuring the effects of novel anti-inflammatory drugs, as these drugs often cause only small effects on lung function. Measurements that demonstrate the pharmacological and clinical effects of these drugs are needed. Furthermore, we now recognise that only subgroups of patients are likely to respond to these novel drugs, so using biomarkers to determine the clinical phenotype most suitable for such therapies is important. An endotype is a subtype of a (clinical) condition defined by a distinct pathophysiological mechanism. An endotype-driven approach may be more helpful in drug development, enabling drugs to be targeted specifically towards specific biological mechanisms rather than clinical characteristics. This requires the development of biomarkers to define endotypes and/or to measure drug effects. This newer approach should continue alongside efforts to optimise the measurement of clinical endpoints, including patient-reported outcome measurements, required by drug regulatory authorities.

show abstract

Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects – A double blind, randomized, placebo-controlled, cross-over clinical trial

Cited by 26 publications

References 27 publications

Selectins and Their Ligands as Potential Immunotherapeutic Targets in Neurological Diseases

Selectins and Their Ligands as Potential Immunotherapeutic Targets in Neurological Diseases

The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers

Evaluation of New Drugs for Asthma and COPD: Endpoints, Biomarkers and Clinical Trial Design

Contact Info

Product

Resources

About